Acute Lymphoblastic Leukemia Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Clinical Trials

Determining the Mechanisms of Loss of CAR T Cell Persistence
Conditions:   Acute Lymphoblastic Leukemia With Failed Remission;   Acute Lymphoblastic Leukemia Not Having Achieved Remission;   Acute Lymphoblastic Leukemia, Pediatric;   Acute Lymphoblastic Leukemia, Adult;   Acute Lymphoblastic Leukemia, in Relapse Intervention:   Sponsor:   University College, London Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2023 Category: Research Source Type: clinical trials

Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCT
Conditions:   Allogeneic Hematopoietic Stem Cell Transplantation;   Acute Lymphoblastic Leukemia Intervention:   Drug: VEN+AZA+Modified BUCY Sponsor:   The First Affiliated Hospital of Soochow University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2023 Category: Research Source Type: clinical trials

Determining the Mechanisms of Loss of CAR T Cell Persistence
Conditions:   Acute Lymphoblastic Leukemia With Failed Remission;   Acute Lymphoblastic Leukemia Not Having Achieved Remission;   Acute Lymphoblastic Leukemia, Pediatric;   Acute Lymphoblastic Leukemia, Adult;   Acute Lymphoblastic Leukemia, in Relapse Intervention:   Sponsor:   University College, London Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2023 Category: Research Source Type: clinical trials

Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCT
Conditions:   Allogeneic Hematopoietic Stem Cell Transplantation;   Acute Lymphoblastic Leukemia Intervention:   Drug: VEN+AZA+Modified BUCY Sponsor:   The First Affiliated Hospital of Soochow University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2023 Category: Research Source Type: clinical trials

Determining the Mechanisms of Loss of CAR T Cell Persistence
Conditions:   Acute Lymphoblastic Leukemia With Failed Remission;   Acute Lymphoblastic Leukemia Not Having Achieved Remission;   Acute Lymphoblastic Leukemia, Pediatric;   Acute Lymphoblastic Leukemia, Adult;   Acute Lymphoblastic Leukemia, in Relapse Intervention:   Sponsor:   University College, London Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2023 Category: Research Source Type: clinical trials

Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCT
Conditions:   Allogeneic Hematopoietic Stem Cell Transplantation;   Acute Lymphoblastic Leukemia Intervention:   Drug: VEN+AZA+Modified BUCY Sponsor:   The First Affiliated Hospital of Soochow University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2023 Category: Research Source Type: clinical trials

Determining the Mechanisms of Loss of CAR T Cell Persistence
Conditions:   Acute Lymphoblastic Leukemia With Failed Remission;   Acute Lymphoblastic Leukemia Not Having Achieved Remission;   Acute Lymphoblastic Leukemia, Pediatric;   Acute Lymphoblastic Leukemia, Adult;   Acute Lymphoblastic Leukemia, in Relapse Intervention:   Sponsor:   University College, London Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2023 Category: Research Source Type: clinical trials

Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCT
Conditions:   Allogeneic Hematopoietic Stem Cell Transplantation;   Acute Lymphoblastic Leukemia Intervention:   Drug: VEN+AZA+Modified BUCY Sponsor:   The First Affiliated Hospital of Soochow University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2023 Category: Research Source Type: clinical trials

Determining the Mechanisms of Loss of CAR T Cell Persistence
Conditions:   Acute Lymphoblastic Leukemia With Failed Remission;   Acute Lymphoblastic Leukemia Not Having Achieved Remission;   Acute Lymphoblastic Leukemia, Pediatric;   Acute Lymphoblastic Leukemia, Adult;   Acute Lymphoblastic Leukemia, in Relapse Intervention:   Sponsor:   University College, London Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2023 Category: Research Source Type: clinical trials

Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCT
Conditions:   Allogeneic Hematopoietic Stem Cell Transplantation;   Acute Lymphoblastic Leukemia Intervention:   Drug: VEN+AZA+Modified BUCY Sponsor:   The First Affiliated Hospital of Soochow University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2023 Category: Research Source Type: clinical trials

Determining the Mechanisms of Loss of CAR T Cell Persistence
Conditions:   Acute Lymphoblastic Leukemia With Failed Remission;   Acute Lymphoblastic Leukemia Not Having Achieved Remission;   Acute Lymphoblastic Leukemia, Pediatric;   Acute Lymphoblastic Leukemia, Adult;   Acute Lymphoblastic Leukemia, in Relapse Intervention:   Sponsor:   University College, London Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2023 Category: Research Source Type: clinical trials

Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCT
Conditions:   Allogeneic Hematopoietic Stem Cell Transplantation;   Acute Lymphoblastic Leukemia Intervention:   Drug: VEN+AZA+Modified BUCY Sponsor:   The First Affiliated Hospital of Soochow University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2023 Category: Research Source Type: clinical trials

Determining the Mechanisms of Loss of CAR T Cell Persistence
Conditions:   Acute Lymphoblastic Leukemia With Failed Remission;   Acute Lymphoblastic Leukemia Not Having Achieved Remission;   Acute Lymphoblastic Leukemia, Pediatric;   Acute Lymphoblastic Leukemia, Adult;   Acute Lymphoblastic Leukemia, in Relapse Intervention:   Sponsor:   University College, London Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2023 Category: Research Source Type: clinical trials

Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCT
Conditions:   Allogeneic Hematopoietic Stem Cell Transplantation;   Acute Lymphoblastic Leukemia Intervention:   Drug: VEN+AZA+Modified BUCY Sponsor:   The First Affiliated Hospital of Soochow University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2023 Category: Research Source Type: clinical trials